Drugs for the Treatment of Respiratory Diseases

Respiratory diseases affect millions of people each year and represent a major health burden around the world. This timely reference surveys and evaluates the drug treatments available for the main categories of lung diseases including asthma and chronic obstructive pulmonary disease, lung cancer, cystic fibrosis, pulmonary vascular disease, lung cancer, and respiratory infections. The recent increase in asthma in certain populations underlines the importance of finding effective new treatments for these diseases. This publication, a comprehensive reference, is one of the first to survey current and novel drug treatments for this group of diseases. It is certain to establish itself as an essential source of reference for respiratory physicians, clinicians and clinical pharmacologists.
Drugs for the Treatment of Respiratory Diseases

EDITED BY

Domenico Spina
The Sackler Institute of Pulmonary Pharmacology,
King's College London, UK

Clive P. Page
The Sackler Institute of Pulmonary Pharmacology,
King's College London, UK

William J. Metzger
National Jewish Medical and Research Center, Denver, CO, USA

AND

Brian J. O'Connor
The Sackler Institute of Pulmonary Pharmacology,
King's College London, UK
Library of Congress Cataloguing in Publication data

Drugs for the treatment of respiratory diseases / edited by Domenico Spina . . . [et. al.].
   p.; cm.
   Includes bibliographical references and index.
   ISBN 0 521 77321 0 (hardback)
   use. 3. Respiratory System Agents – therapeutic use. WF 145 D7947 2002]
   RC756 .D784 2002
   616.2’4061–dc21 2002023390

   ISBN 978 0 521 77321 8 Hardback

Every effort has been made in preparing this book to provide accurate and up-to-
date information which is in accord with accepted standards and practice at the
time of publication. Nevertheless, the authors, editors and publisher can make no
warranties that the information contained herein is totally free from error, not least
because clinical standards are constantly changing through research and
regulation. The authors, editors and publisher therefore disclaim all liability for
direct or consequential damages resulting from the use of material contained in this
book. Readers are strongly advised to pay careful attention to information provided
by the manufacturer of any drugs or equipment that they plan to use.
# Contents

<table>
<thead>
<tr>
<th>List of contributors</th>
<th>vii</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>xi</td>
</tr>
</tbody>
</table>

## Part I Asthma and COPD

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pathology of asthma and COPD: inflammation and structure</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Peter K. Jeffery</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Glucocorticosteroids</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Peter J. Barnes</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>$\beta_2$-adrenoceptor agonists</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Domenico Spina, Clive P. Page and Brian J. O'Connor</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Anticholinergic bronchodilators</td>
<td>105</td>
</tr>
<tr>
<td></td>
<td>Jeremy M. Segal and Nicholas J. Gross</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Antiallergic drugs</td>
<td>119</td>
</tr>
<tr>
<td></td>
<td>Masakazu Ichinose</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Drugs affecting the synthesis and action of leukotrienes</td>
<td>124</td>
</tr>
<tr>
<td></td>
<td>Paul M. O’Byrne</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Theophylline and selective phosphodiesterase inhibitors in the treatment of respiratory disease</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td>Neil A. Jones, Domenico Spina and Clive P. Page</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Potential therapeutic effects of potassium channel openers in respiratory diseases</td>
<td>172</td>
</tr>
<tr>
<td></td>
<td>Ahmed Z. El-Hashim</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Tachykinin and kinin antagonants</td>
<td>184</td>
</tr>
<tr>
<td></td>
<td>Pierangelo Geppetti</td>
<td></td>
</tr>
</tbody>
</table>
Contents

10 Drugs affecting IgE (synthesis inhibitors and monoclonal antibodies) 195
   Lawrence G. Garland and Alan G. Lamont
11 Drugs targeting cell signalling 218
   Brydon L. Bennett, Yoshitaka Satoh and Alan J. Lewis

Part II Diffuse parenchymal lung disease

12 Current approaches to the treatment of parenchymal lung diseases 247
   Joseph P. Lynch III and Michael Keane
13 Drug treatments of the future in fibrotic lung disease 336
   Athol U. Wells

Part III Infection

14 Current and future management of pneumonia 363
   Mario Cazzola and Maria G. Matera
15 Current treatment of chronic bronchial suppuration 403
   Robert Wilson
16 Current and future treatment of cystic fibrosis 428
   R.G. Gary Ruiz, Hilary H. Wyatt and John F. Price

Part IV Pulmonary vascular diseases

17 Pathophysiology of pulmonary vascular disease 453
   Sanjay Mehta and David G. McCormack
18 Current treatment of pulmonary vascular diseases 475
   Tarek Saba and Andrew Peacock
19 Future treatment of pulmonary vascular diseases 504
   Norbert F. Voelkel, Mark W. Geraci and Steven Abman

Part V Lung cancer

20 Molecular pathology of lung cancer 519
   Ignacio I. Wistuba and Adi F. Gazdar
21 Small cell lung cancer 535
   Desmond N. Carney

Part VI Cough

22 Mechanisms of cough 553
   John J. Adcock
23 Current treatment of cough 565
   Peter V. Dicpinigaitis
Index 579
Colour plate section between pp. 12 and 13.
Contributors

Editors

Domenico Spina
The Sackler Institute of Pulmonary Pharmacology
Department of Respiratory Medicine and Allergy
GKT School of Medicine
King's College London
Bessemer Road
London SE5 9PJ, UK

Clive P. Page
The Sackler Institute of Pulmonary Pharmacology
Division of Pharmacology and Therapeutics
GKT School of Biomedical Science
5th Floor Hodgkin Building
Guy's Campus
London SE1 1UJ, UK

W.J. Metzger*
National Jewish Medical and Research Center
1400 Jackson Street, Denver, CO 80206, USA

Brian J. O'Connor
The Sackler Institute of Pulmonary Pharmacology
Department of Respiratory Medicine and Allergy
GKT School of Medicine
King's College London
Bessemer Road
London SE5 9PJ, UK

*now deceased
Contributors

Steven Abman
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado Health Sciences Center
4200 East Ninth Avenue, C272
Denver, CO 80262, USA

John J. Adcock
Pneumolabs (UK) Ltd
NPIMR, Y Block
Watford Road
Harrow, Middlesex HA1 3UJ, UK

Peter J. Barnes
Department of Thoracic Medicine
National Heart and Lung Institute
Imperial College School of Medicine
Dovehouse Street
London SW3 6LY, UK

Brydon L. Bennett
Signal Research Division
Celgene Corporation
5555 Oberlin Drive
San Diego, CA 92121, USA

Desmond N. Carney
Department of Medical Oncology
Mater Hospital
Dublin 7, Ireland

Mario Cazzola
Department of Respiratory Medicine
Division of Pneumology and Allergology
A. Cardarelli Hospital
Naples, Italy

Peter V. Dicpinigaitis
Department of Medicine
Albert Einstein College of Medicine
Bronx, New York, USA

Ahmed Z. El-Hashim
Department of Applied Therapeutics
Faculty of Pharmacy, Kuwait University
PO Box 249, Kuwait, SAFAT 13110

Lawrence G. Garland
Formerly at Acambis PLC
100 Fulbourn Road
Cambridge CB1 9PT, UK

Adi F. Gazdar
Hamon Center for Therapeutic Oncology Research
NB8.106, UT Southwestern Medical Center
5323 Harry Hines Blvd
Dallas, TX 75235-8593, USA

Pierangelo Geppetti
Department of Experimental and Clinical Medicine
Pharmacology Unit, University of Ferrara
Via Fossato di Mortara 19, 44100, Italy

Mark W. Geraci
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado Health Sciences Center
4200 East Ninth Avenue, C272
Denver, CO 80262, USA

Nicholas J. Gross
Building 1, Room A342, Hines VA Hospital
Roosevelt and 5th Avenues
Hines, IL 60141, USA

Masakazu Ichinose
Department of Respiratory and Infectious Diseases
Tohoku University School of Medicine
1-1 Seiryo-machi Aoba-ku
Sendai 980 8574, Japan

Peter K. Jeffery
Imperial College at the Royal Brompton Hospital,
National Heart and Lung Institute
Sydney Street
London SW3 6NP, UK

Neil A. Jones
The Sackler Institute of Pulmonary Pharmacology
Pharmacology and Therapeutics Division
GKT School of Biomedical Sciences
5th Floor Hodgkin Building
Guy's Campus, London SE1 1UL, UK
List of contributors

Michael Keane
Division of Pulmonary and Critical Care Medicine
Department of Internal Medicine
University of Michigan Medical Center
3916 Taubman Center, Box 0360
Ann Arbor, MI 48109-0360, USA

Alan G. Lamont
Catalyst Biomedica Ltd
183 Euston Road
London NW1 2BE, UK (formerly at Acambis PLC)

Alan J. Lewis
Signal Research Division
Celgene Corporation
5555 Oberlin Drive, San Diego, CA 92121, USA

Joseph P. Lynch III
Division of Pulmonary and Critical Care Medicine
Department of Internal Medicine
University of Michigan Medical Center
3916 Taubman Center, Box 0360
Ann Arbor, MI 48109-0360, USA

David G. McCormack
A.C. Burton Vascular Research Laboratory
Division of Respirology, London Health Services Centre
Departments of Medicine, Pharmacology and Toxicology
University of Western Ontario
London, Ontario, Canada

Maria G. Matera
Institute of Pharmacology and Toxicology
Medical School
Second Neapolitan University, Naples, Italy

Sanjay Mehta
A.C. Burton Vascular Research Laboratory
Division of Respirology, London Health Services Centre
Departments of Medicine, Pharmacology and Toxicology
University of Western Ontario, London, Ontario, Canada

Paul M. O’Byrne
Firestone Regional Chest and Allergy Unit
St Joseph’s Hospital, 50 Charlton Avenue East
Hamilton, Ontario L8N 4A6, Canada

Brian J. O’Connor
The Sackler Institute of Pulmonary Pharmacology
Department of Respiratory Medicine
King’s College London
Bessemer Road, London SE5 9PJ, UK

Clive P. Page
The Sackler Institute of Pulmonary Pharmacology
Division of Pharmacology and Therapeutics
GKT School of Biomedical Science
5th Floor Hodgkin Building
Guy’s Campus, London, SE1 1UL, UK

Andrew Peacock
Scottish Pulmonary Vascular Unit, Level 8, Western Infirmary
Dumbarton Road, Glasgow G11 6NT, UK

John F. Price
Department of Child Health, King’s College Hospital
Denmark Hill, London SE5 9RS, UK

R.G. Gary Ruiz
Department of Child Health, King’s College Hospital
Denmark Hill, London SE5 9RS, UK

Tarek Saba
Scottish Pulmonary Vascular Unit, Level 8, Western Infirmary
Dumbarton Road, Glasgow G11 6NT, UK

Yoshitaka Satoh
Signal Research Division
Celgene Corporation
5555 Oberlin Drive
San Diego, CA 92121, USA

Jeremy M. Segal
Departments of Medicine and Molecular Biochemistry
Stritch School of Medicine, Loyola University of Chicago, IL, USA

Domenico Spina
The Sackler Institute of Pulmonary Pharmacology
Department of Respiratory Medicine and Allergy
King’s College London
Bessemer Road, London SE5 9PJ, UK
List of contributors

Norbert F. Voelkel
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado Health Sciences Center
4200 East Ninth Avenue, C272
Denver, CO 80262, USA

Athol U. Wells
Interstitial Lung Disease Unit
Departments of Radiology, Pathology and Physiology
Royal Brompton Hospital
Sydney Street, London SW3 6NP, UK

Robert Wilson
Royal Brompton Hospital
Sydney Street, London SW3 6NP, UK

Ignacio I. Wistuba
Department of Pathology
Pontificia Universidad Catolica de Chile
PO Box 114-D, Santiago, Chile

Hilary H. Wyatt
Department of Child Health, King's College Hospital
Denmark Hill, London SE5 9RS, UK
Preface

In 1991, Jim Metzger and I edited a volume called *Drugs and the Lung*. A decade on, we thought that sufficient new information had been obtained to warrant a new book and this volume reflects the culmination of a considerable effort of many individuals including my new co-editors Dom Spina and Brian O’Connor, plus all the contributing authors. Lung diseases still represent a considerable burden to the healthcare system globally and have significant impact on the socio-economic situation in many countries around the world. The incidence of asthma continues to rise in many western countries with no cure in sight. Furthermore, tuberculosis, pulmonary infections and COPD are far from optimally controlled and not surprisingly therefore, there continues to be a considerable amount of interest in the development of novel therapies for a wider range of lung diseases. Perhaps, just as importantly, continual appraisal of optimal use of existing therapies continues with guidelines for the treatment of asthma and COPD now being commonplace in many western societies. This book represents a comprehensive collection of chapters regarding the current status of a wide range of drugs in use for the treatment of lung diseases, as well as providing an excellent overview of the many new drug classes under development. We have tried to ensure that, where possible, all chapters have a bias towards clinical information about drugs, but drawing on information from in vitro and animal studies where appropriate. We hope this book will be of interest to clinicians, scientists and students as a resource about drugs for the treatment of respiratory diseases.
Tragically, my colleague and friend Jim Metzger died half-way through this project. Jim was an excellent mentor to me along with fellow editors and was responsible for teaching me a lot about allergy and clinical immunology. I share his tragic loss with his devoted family and many friends. Jim had contributed enormously to the field of lung diseases and we hope this book will help provide a lasting memory of him.

Clive P. Page
on behalf of all the editors
March 2002